Viracta Therapeutics (VIRX) Q2 2024 earnings summary

Executive summary

• Positive combined Stage 1 and 2 results from the Phase 2 NAVAL-1 trial in relapsed/refractory EBV-positive PTCL, with substantial antitumor activity and a well-tolerated safety profile.

• Viracta Therapeutics is a clinical-stage oncology company focused on virus-associated cancers, with its lead candidate Nana-val in pivotal trials for EBV+ lymphoma; the EBV+ solid tumor program was paused in August 2024 to focus resources on lymphoma.

• Robust clinical response in the second-line EBV+ PTCL subpopulation, with ORR up to 67% and CRR up to 33% in efficacy-evaluable patients.

• Pipeline reprioritization to focus on EBV+ lymphoma, pausing the EBV+ solid tumor program and implementing a 23% workforce reduction.

• Appointment of Michael Faerm as Chief Financial Officer.

Financial highlights

• Q2 2024 net loss was $9.8 million ($0.25/share), compared to $12.5 million ($0.32/share) in Q2 2023; six-month net loss was $19.0 million ($0.48/share), improved from $24.7 million ($0.64/share) in 2023, aided by a $5.0 million milestone income.

• Cash, cash equivalents, and short-term investments totaled $30.0 million as of June 30, 2024, expected to fund operations into late Q1 2025.

• Research and development expenses for Q2 2024 were $6.5 million, down from $8.2 million in Q2 2023; G&A expenses were $3.0 million, down from $4.3 million.

• Net cash used in operating activities was $17.7 million for the six months ended June 30, 2024, compared to $19.3 million in the prior year period.

• Total assets were $31.3 million and stockholders' equity was $2.7 million as of June 30, 2024.

Outlook and guidance

• Management expects continued net losses and negative cash flows for at least the next several years and will require additional capital to fund operations.

• Focused on advancing Nana-val in second-line EBV+ PTCL, with a randomized controlled trial planned for H2 2025 and NDA filing for accelerated approval targeted in 2026.

• Additional data from the NAVAL-1 expansion phase in second-line EBV+ PTCL expected in Q4 2024.

• Existing cash and investments may not be sufficient to fund operations for twelve months from the financial statement issuance date; cash runway expected to last into late Q1 2025.